The introduction of brachytherapy to the country of Botswana by Clayman, Rebecca
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2015
The introduction of brachytherapy
to the country of Botswana
https://hdl.handle.net/2144/16131
Boston University
	   	   	  
BOSTON UNIVERSITY 
 
SCHOOL OF MEDICINE 
 
 
 
 
 
 
Thesis 
 
 
 
 
 
 
THE INTRODUCTION OF BRACHYTHERAPY 
 
TO THE COUNTRY OF BOTSWANA 
 
 
 
 
by 
 
 
 
 
REBECCA H. CLAYMAN 
 
B.S., University of Wisconsin-Madison, 2011 
 
 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Master of Science 
 
2015  
	   	   	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2015 by 
 REBECCA H. CLAYMAN 
 All rights reserved  
	   	   	  
Approved by 
 
 
 
 
First Reader   
 Vickery Trinkaus-Randall, Ph.D. 
 Professor of Biochemistry and Ophthalmology  
 
 
 
 
Second Reader   
 Jason A. Efstathiou, M.D., DPhil 
 Associate Professor of Radiation Oncology 
 Harvard Medical School  
 
 
 
	  	   iv 
THE INTRODUCTION OF BRACHYTHERAPY 
TO THE COUNTRY OF BOTSWANA 
REBECCA H. CLAYMAN 
ABSTRACT 
Low and middle-income countries (LMICs) around the world are experiencing a 
global cancer crisis. For treatable disease, cancer specific mortality in LMICs is 
much higher than in high-income countries. Botswana is a middle-income country 
in Sub-Saharan Africa that had its population decimated by the AIDS epidemic. 
In the aftermath and due to the successful implementation of an anti-retroviral 
program, patients are living longer and are developing cancer. Cervical cancer is 
one of the leading causes of death in women around the world, but it is curable. 
Patients in Botswana live far from treatment centers and therefore often present 
with locally advanced disease that can be cured with a combination of 
chemotherapy, external beam radiation therapy and brachytherapy. 
 
The goal of this present study is to describe the challenges and implementation 
of brachytherapy in the country of Botswana in 2012 and to report its uses within 
the cervical cancer population between 2012 and 2014. 
 
The government of Botswana recognized that there was a need for in country 
brachytherapy to help reduce the cervical cancer burden. A public-private 
partnership was negotiated through the government of Botswana in order to bring 
	  	   v 
brachytherapy into the country. In March 2011, a Nucletron HDR-Brachytherapy 
unit that uses Ir-192 was installed at Gaborone Private Hospital. Longitudinal 
support from international partners provided instruction in insertion, dosimetry, 
physics and management of complications.  
 
The initial burden of patients presented with severe cervical fibrosis and vaginal 
stenosis due to late presentation of disease. This resulted in numerous 
complications in the first treatments, which included failed insertions, perforations 
and bleeding. Following training and support from international partners, 
complications have been reduced. There are about 45 insertions performed each 
month, with an average of 3 insertions per patient.  
 
Introduction of HDR Brachytherapy to Botswana has led to decreased treatment 
time, reduced complications, increased patient compliance and projected 
improved survival. Implementation of brachytherapy was facilitated by a public-
private partnership and onsite mentorship by expert clinicians. Further research 
is needed to evaluate impact on patient quality of life and survival, and whether 
this experience can be replicated for other tumor sites.  
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THE INTRODUCTION OF BRACHYTHERAPY 
TO THE COUNTRY OF BOTSWANA 	  
INTRODUCTION 	  
Cancer Care in Low and Middle Income Countries 
The global burden of cancer accounted for 8.2 million deaths in 2012, with over 
65% of cancer-related deaths occurring in low and middle-income countries 
(LMICs) (World Health Organization (WHO), n.d). Cancer specific mortality is 
much higher in low-income countries than in high-income countries for treatable 
disease (Farmer et al., 2010). Late presentation of disease is a major challenge 
in cancer detection and treatment in LMICs due to a lack of medical infrastructure 
and routine screening processes (Kingham et al., 2013).  
 
All forty-seven African countries are currently classified as developing nations, 
with many having a low or middle-income status (World Bank, 2015). While 
advances in cancer detection and treatment are being made in wealthy nations 
around the world, advances in cancer care have been challenging in Sub-
Saharan Africa due in part to a limited number of educated health care workers 
(Kingham et al., 2013). Citizens who wish to obtain a medical education may 
leave their native countries to finish training, and many do not return to practice. 
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This is a factor that contributes to a limited number of native healthcare 
professionals throughout Sub-Saharan Africa.  
 
Cancer diagnosis in high income countries usually includes clinical examination, 
biopsy of mass and regional lymph nodes and a combination of scans to detect 
the extent of the cancer. Magnetic Resonance Imaging (MRI), Computerized 
Tomography (CT) and Positron Emission Tomography (PET) scans are not 
always accessible in the developing world, so physicians rely on less advanced 
detection techniques.  When available, chest X-Rays and ultrasound can be used 
to help diagnose and stage cancer in LMICs. After a patient has been diagnosed, 
it is essential that adequate equipment, facilities and human resources be 
provided to ensure that patients receive the best treatment for their cancer (Bese 
et al., 2008).  In LMICs, treatment also poses a challenge, as there may be 
inadequate surgical, chemotherapy and radiation therapy resources available.  
 
Cervical Cancer 
In 2014, cervical cancer was the fourth most common malignancy among women 
worldwide (WHO, 2014). Cervical cancer is one of six cancers associated with 
the human papilloma virus (HPV) (Center for Disease Control (CDC), n.d.) and 
can result from persistence of an HPV infection. If an HPV infection is present at 
the transformation zone in the cervix (between the ectocervix and endocervix), 
the epithelial cells may progress to pre-cancerous lesions. Eighty to ninety 
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percent of cervical cancers are squamous cell carcinomas, while 10–20% are 
adenocarcinomas (Clinical Radiation Oncology, Gunderson and Tepper). Risks 
for developing invasive cervical cancers include multiple sexual partners, early 
onset of sexual activity and immunosuppression (Klumb et al., 2010, Ramogola-
Masire et al., 2014). Patients with a compromised immune system (i.e. patients 
with Human Immunodeficiency Virus (HIV)) may be more likely to have a 
persistent HPV infection which can cause precancerous lesions to evolve into 
cancer.  
 
In more developed regions of the world, cervical cancer can be screened for and 
diagnosed with papanicolaou (PAP) tests, but they are not readily available for 
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routine use in LMICs. Because screening access is limited, women often present 
with advanced cervical carcinoma. Locally advanced cervical cancer can be 
treated with a combination of external beam radiation therapy (EBRT), cervical 
brachytherapy, and cisplatin-based chemotherapy, but in LMICs there are limited 
trained radiation oncologists and access to radiation therapy equipment 
(Kingham et al., 2013; Abdel-Wahab et al. 2013). 
 
There are two vaccinations for HPV that are regularly given in the United States, 
but they are not routine in developing nations.  The quadrivalent vaccine protects 
against HPV types 6, 11, 16 and 18 while the bivalent vaccine protects only 
against types 16 and 18. The vaccine is expensive, around $300 for three doses 
(cancer.org). Although HPV 16 and 18 are commonly known to cause cervical 
cancer in the United States, the most prevalent subtypes in Sub-Saharan Africa 
are still being investigated (Ramogola-Masire et al. 2011, Ermel et al., 2014).  
 
Prevention and Screening 
Two types of screening for cervical cancer are utilized regularly in the developed 
world. PAP tests involve retrieval of a sample of cells from the transformation 
zone between the ecto- and endo- cervix. Cytology can then be performed on the 
sample; which allows for the identification of atypical cells. HPV testing can also 
be performed, and both a PAP test and HPV test can be performed together 
(known as a “co-test”).   
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Cervical cancer screening recommendations in the United States include a PAP 
test at intervals of every three years for women under the age of 30 (Committee 
on Practice Bulletins- Gynecology, 2012) For women over the age of 30, PAP 
tests every three years or a co-test every five years is recommended if initial 
screening tests are negative (Vesco KK et al., 2011). 
 
In LMICs, access to cervical cancer screening is not always available (Denny et 
al., 2015).  Women do not have access to routine screening, and may only be 
screened twice in their lifetime (Denny et al., 2015). In resource limited settings, 
patients live far from hospitals that can perform and process PAP tests, read the 
cytology, and treat pre-cancerous lesions detected by the test.  In a study 
performed on a subset of the HIV-positive population, only 1/3 of the women had 
been screened in their lifetime (Ramogola-Maisaire et al., 2012). Recently, 
screening methods have been developed that allow for rapid diagnosis of 
cervical lesions and removal of these lesions before they progress to cancer. 
Visual inspection with acetic acid (VIA) has emerged as an alternative screening 
technique to detect cervical lesions. VIA uses a Q-tip covered in acetic acid to 
detect dysplastic cervical epithelium.  When the acetic acid is applied to the 
transformation zone of the cervix, normal epithelium appears pink while 
dysplastic or neoplastic epithelium appears white. VIA can detect low-grade 
cervical lesions that are visible to the eye, and it can be an affordable alternative 
to expensive PAP tests in LMICs (Sahasrabuddhe et al., 2012).  
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Diagnosis, Staging and 
Treatment 
In the United States and 
other developed nations, 
cervical cancer can be 
diagnosed at an early stage 
with routine PAP tests and 
HPV testing. Treatment 
recommendations for early 
stage cervical cancer can be 
seen in Table 1. In the 
developing world, cervical 
cancer is often not detected 
until it is advanced, and it can then be treated with a combination of 
chemotherapy and radiation therapy (chemoRT). Radiation therapy includes 
external beam radiation therapy (EBRT) and brachytherapy. Brachytherapy is the 
direct insertion of radiation into the cervix, and can be used to help gain complete 
local control of the disease. There are three different types of cervical 
brachytherapy: intracavitary brachytherapy, interstitial brachytherapy and pulse-
dose rate brachytherapy. EBRT and Brachytherapy are given in combination to 
maximize the dose given to point A (Figure 2) and to control the disease.  
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Radiation Therapy in Sub-Saharan Africa  
Radiation therapy is a key component in multidisciplinary cancer care, and a 
single machine can deliver radiation to thousands of patients. The International 
Atomic Energy Agency recommends one EBRT machine for every quarter million 
to half-million people (Abdel-Wahab et al., 2013).  Even though radiotherapy is 
recognized as an indispensable tool for the palliation and cure of cancer, the 
IAEA estimates there is a need for an additional 7000 machines to treat the need 
around the world (Jaffray et al., 2014). In 2010, 29 of the 47 countries did not 
offer radiation therapy, making Africa the continent with the least amount of 
radiation resources in the world (Grover et al., 2015). The 160 radiation centers 
are not uniformly spread throughout the continent with the majority concentrated 
in Egypt and South Africa (Figure 3).  
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In Botswana in 2008 there were 0.52 radiotherapy machines per million people, 
and in South Africa, there were 1.89 machines per million people (Abdel-Wahab 
et al., 2013).  The most common radiation treatment throughout Africa is External 
Beam Radiation Therapy (EBRT) using either a Cobalt-60 machine or a Linear 
Accelerator (LINAC). Cobalt-60 units are relatively inexpensive to obtain and 
maintain when compared to the LINAC. They do not require a stable power 
source and are easier to operate and maintain, but they do not deliver as precise 
of a treatment plan.  Cobalt-60 machines also have a radiation source that has 
the potential to harm as it can expose people to high levels of radioactivity. In 
addition due to its portability it can be easily stolen subject the thieves and others 
to harm (Page et al., 2014). The Linac provides substantial advantages with 
regard to beam collimation, conformal therapy, and performing intensity 
modulation (Porter et al., 1999).  Brachytherapy is less common across the 
continent, with only 20 countries having brachytherapy units in 2010.  For 
example, Senegal recently acquired HDR brachytherapy and they have a single 
Cobalt-60 teletherapy unit that provides radiation therapy to a country of 13 
million people and West Africa (Einck et al., 2013).  
 
Radiotherapy itself is a multidisciplinary specialty.  Patients are treated every day 
for a number of weeks (depending upon the type of cancer). Treatment of a 
patient requires a radiation oncologist, medical physicist, radiation therapists, 
dosimetrists, imaging staff and nurses. Radiation oncologists need to be able to 
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consult with others on complex treatment plans. EBRT machines require 
maintenance and engineering expertise in the event that they break down. 
Radiation sources for brachytherapy units need to be replaced every three to four 
months. Power shortages and inadequate engineering support contributes to 
machine downtime in developing countries (Page et al., 2014).  Maintenance 
needs to be completed in a timely manner, so as not to delay treatment for 
patients. In Sub-Saharan Africa, there are limited resources available to keep the 
machines and the treatment running smoothly.  
 
Healthcare and Cervical Cancer in Botswana 
Botswana is a middle-income country that lies in the heart of Sub-Saharan Africa. 
The population of Botswana experienced a devastating decrease due to the 
Autoimmune Deficiency Syndrome (AIDS) epidemic, but the country has 
implemented a successful HIV treatment program (UNAIDS, Global Report 
2013). Botswana is seeing a wave of cancers emerge as patients with HIV are 
living longer (Suneja et al. 2013) and developing cancer. Between 1998 and 
2008, the top cancer sites in the overall population were Kaposi Sarcoma, Cervix 
uteri and Head and Neck (Dryden-Peterson et al., n.d.). 
 
Three types of health care are available in the country of Botswana and include 
public, private and that of a traditional healer.  Healthcare in the public system is 
free, and includes hospitalizations, treatments, laboratory tests and medications 
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(Penn guide/handbook). The current ratio of patients to physicians is 0.3 for 
every 100 people (where in the US it is 2.4 for every 100 people) (World Bank, 
2010). Due to limited medical infrastructure, certain medical services are 
outsourced to neighboring hospitals in South Africa and Zimbabwe. Until 
recently, there was no medical school in Botswana, so physicians who work in 
the country were trained elsewhere. The University of Botswana Medical School 
opened in 2009, and will be able to provide the country with well-educated 
physicians. Patients who have been diagnosed with cancer are referred to one of 
two oncology centers in the capitol city of Gaborone; Princess Marina Hospital 
(PMH) and Gaborone Private Hospital (GPH).  Two public oncology centers, 
Nyangabwe Referral Hospital and Letsholathebe II Memorial Hospital, are in 
operation in the northern part of the country, in Francistown and Maun, 
respectively (Figure 4).  
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Princess Marina Hospital opened its doors in 1966, at the time Botswana gained 
its independence. It is the largest hospital in Botswana and is a major referral 
center for cases that come in from across the country (Figure 5b). In the 1990’s 
there was no dedicated oncology ward in Gaborone; it was a subset of the 
accident and emergency department at PMH (Livingston, 2012). In 2001, the 
Ministry of Health in Botswana created the cancer ward. PMH oncology staff 
includes house officers and full-time attending oncologists who have been 
recruited through either a service program of the government of China or a for-
profit Indian medical staffing company (Efstathiou et al., 2014. Many of these 
contract physicians do not speak English or the national language (Setswana), 
so communication with patients is challenging (Chabner et al., 2013). Recently, 
Botswana Oncology Global Outreach (BOTSOGO) and the MGH Cancer Center 
hired a full time medical oncologist to work in the oncology ward at PMH. Many 
patients at PMH will arrive for appointments in the oncology ward at the 
beginning of a day and may wait 5–6 hours to be seen by a physician 
(Livingston, 2012). 
 
On January 20, 2000, a linear accelerator was installed at GPH and is currently 
the only source of EBRT in Botswana (Figure 5a). It is a clinical accelerator that 
provides radiation with both photons and electrons. There are currently two 
clinical oncologists (with training in both medical and radiation oncology) at GPH.  
Radiation therapy at GPH for public patients is coordinated by PMH oncology. 
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Treatment takes place Monday through Friday between 7AM and 8PM, and 50–
60 patients per day are treated. There are no scheduled appointments for 
patients, they arrive in large groups by bus and wait their turn for their treatment. 
Many patients who come to GPH for treatment are patients at PMH; the 
government pays for their radiation therapy. The Cancer Association of 
Botswana is a voluntary organization that provides community education about 
cancer prevention and health awareness programs. It also maintains an interim 
home for patients who have come from out of town to receive cancer care.  
 
The National Pathology Health Laboratory in Botswana (NHL) receives over 
24,000 PAP specimens each year, (Efstathiou et al., 2014) which overloads the 
few pathologists who work in the country. Knowledge of cervical cancer and 
screening are not very well known throughout the country, but they can be 
improved by working with the patient population as different options become 
readily available (Mingo et al., 2012). In 2009, the government of Botswana 
approved the HPV vaccine, but due to its high cost, women are not routinely 
immunized. The quadrivalent HPV vaccination may be successful in Botswana, 
even though there is evidence that other subtypes are more prevalent throughout 
the population (Firnhaber et al., 2011, Ramogola-Masaire et al., 2014). Although 
there is limited knowledge throughout the country on HPV, many parents in 
Botswana would be supportive of an HPV vaccination for their daughters (DiAngi 
et al., 2011).  
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Unfortunately, in Botswana and other countries in Africa, there are a multitude of 
barriers to cervical cancer screening that include a diverse population, long 
distance to medical centers and an in inherent belief in traditional medicine and 
healers. Gaps in health-care systems make national screening programs difficult 
to maintain (Maseko et al., 2015, McFarland et al., 2013). The Botswana-
University of Pennsylvania collaboration developed a cervical cancer prevention 
and screening program in Gaborone that works to detect low grade cervical 
lesions (Efstathiou et al., 2014). A “see and treat” method for screening cervical 
cancer patients has been developed and implemented that uses acetic acid 
inspection and enhanced digital imaging in women who live in Botswana 
(Ramogola Masaire et al., 2012).  
 
Screening for cervical cancer with high-end microscopy may also serve as a low-
cost, easy to implement alternative to biopsy after a cervical lesion has been 
detected (Quinn et al., 2012).  Patients with cervical cancer in Botswana often 
present with advanced disease, and treatment consists of radiation therapy with 
or without cisplatin based chemotherapy (Bvochara-Nsingo et al., 2014). In “See 
and Treat” clinics that exist as a subset in community clinics in Botswana, 
patients undergo VIA if a suspicion lesion is seen during inspection with a 
speculum. VIA can be performed with white household vinegar (Ramogola 
Masaire et al., 2012).  Cryotherapy can be performed when low grade lesions are 
detected, colposcopy can be performed in women with higher grade lesions, and 
	  17 
women whose lesions extend to the vaginal wall will be sent for cone biopsy or 
hysterectomy. 
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Objectives 
As shown in previous papers and studies, cervical cancer has been a major 
cause of death in low and middle-income countries. Cervical cancer can be cured 
if detected early and treated.  The goal of this present study is to describe the 
challenges and implementation of brachytherapy in the country of Botswana in 
2012 and to report its uses within the cervical cancer population between 2012 
and 2014.  
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METHODS 
 
Bringing brachytherapy to Botswana  
The government of Botswana recognized that there was a need for in country 
brachytherapy to help reduce the cervical cancer burden. A public-private 
partnership was negotiated through the government of Botswana in order to bring 
brachytherapy into the country. GPH would acquire the equipment and the 
government would facilitate procurement of the radiation source and fund 
treatment. Early in 2011, training by Elekta (manufacturer of the brachytherapy 
machine) was provided and on March 16, 2011, a Nucletron HDR brachytherapy 
unit that uses Iridium 192 was installed. The radiation source arrived in the 
beginning of 2012, and the first cervical cancer patient was treated with 
brachytherapy in January 2012.  
   
Training and Longitudinal Support from Radiation Oncologists 
Beginning in February 2012, longitudinal support from international partners 
(Botswana Oncology Global Outreach (BOTSOGO)/Harvard and the Botswana-
University of Pennsylvania partnership) provided support and instruction in 
insertion, dosimetry, physics, management of complications and nursing. Two 
trips by BOTSOGO were timed to coincide with the arrival of the radiation source 
for the brachytherapy unit at GPH February 2012. Radiation oncologists and a 
medical physicist from Massachusetts General Hospital (MGH) worked with the 
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attending radiation oncologist, radiation therapist, dosimetrist and medical 
physicist at GPH to provide guidance on brachytherapy treatment planning, 
image guidance, source insertion and patient treatment (Efstathiou et al., 2014). 
Another trip in September 2012 focused on quality assurance training for the staff 
in the radiation oncology department at GPH.  Radiation oncology staff from 
MGH worked with the oncology staff at GPH to put together treatment checklists 
and brainstorm potential ideas on how to successfully treat more patients every 
day.  The trip also focused on training staff to use a titanium applicator set and 
alleviating the backlog of patients who had been waiting for brachytherapy 
treatment.  
 
Since September 2012, there have been other trips to Gaborone, made by both 
radiation oncologists from MGH and the University of Pennsylvania. The 
University of Pennsylvania currently has a full time radiation oncologist working 
with the two attending clinical oncologists at GPH. BOTSOGO planned the 
countries first oncology symposium that took place in May 2014. It was created to 
allow both public and private healthcare workers to come together to share their 
knowledge with oncology experts visiting from around the world.  
 
BOTSOGO has made other efforts in order to help build sustainable cancer 
expertise throughout the country of Botswana.  A full-time medical oncologist is 
on the ground treating patients at PMH. A multidisciplinary tumor board occurs 
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each month and connects site experts to the oncology community in Botswana. 
Physicians from Botswana present a difficult or challenging case, and they are 
able to discuss with the MGH oncology community. More importantly, the tumor 
board brings together the oncologists from both PMH and GPH, and they are 
able to collaborate and discuss patients together.  
 
Research 
After approval from the Institutional Review Board in Botswana through the 
Botswana Harvard AIDS Institute Partnership, a list of oncology patients from the 
Botswana Prospective Cancer Cohort (BPCC) from 2011–2014 was generated. 
This list was used to identify oncology patients who had or had not received 
radiation therapy at GPH. MOSAIQ is a software system that is used to centralize 
radiation oncology treatment information, and is used at GPH. 1158 oncology 
charts were reviewed retrospectively in MOSAIQ at GPH. Of the 1158 oncology 
patients, 260 were treated for cervical cancer at PMH and GPH, and their charts 
were reviewed in detail.  
 
The data collection form that was used is shown in Figure 6. Additional 
information including dates of missed or delayed treatments was also collected.  
Missed treatments were defined as receiving less than the prescribed radiation 
dose. Delays in treatment were defined as missing more than two consecutive 
days that did not occur over a weekend. Data from treatment completion 
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summaries generated by the attending radiation oncologist at GPH was also 
recorded. Brachytherapy data was recorded from the treatment completion 
summaries and from patient’s paper records at GPH, as detailed brachytherapy 
information has not yet been recorded in MOSAIQ. Microsoft excel was used to 
calculate descriptive statistics based on the radiation data collected from 
MOSAIQ.  
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RESULTS 
 
The Nucletron 
high dose rate 
(HDR) 
brachytherapy unit 
was delivered in 
early 2011, and it 
went into clinical 
use on 1/23/2012 
due to delays in 
obtaining the 
radiation source 
(Figure 7). Following training and support from BOTSOGO and the Botswana-
University of Pennsylvania partnership and elimination of a backlog of patients, 
complications have been markedly reduced. After more than 1200 insertions on 
over 300 patients, there have been 16 insertion failures, 7 perforations, 2 
episodes of severe bleeding and no mortality during the procedure or from 
related complications. Since the implementation of the brachytherapy equipment 
in 2012, about 45 brachytherapy insertions are performed each month at GPH 
with an average of three insertions per patient (Table 2).  
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260 patients from 2011–2014 were diagnosed with cervical cancer and recorded 
in the BPCC. Patients were recorded in the BPCC at time of diagnosis. Average 
age at the start of treatment was 49 years (range 26–84 years old).  Of those 260 
patients, 240 were treated with radiation therapy, 161 with curative intent, 31 with 
palliative intent and 48 unknown.  The median time from the start to end of 
treatment was 43 days (Range 1–201). Patients who were diagnosed and treated 
for cervical cancer before January 2012 would have been referred to South 
Africa for brachytherapy treatment, so these numbers are not reflective of 
brachytherapy patients before 2012. Thirty-eight patients missed at least one 
radiation treatment, and 157 patients had delays in receiving their radiotherapy. 
For patients treated with curative intent, 85% completed treatment course within 
the recommended 56 days.  
 
Median brachytherapy dose for the 172 patients who received brachytherapy 
was 2100Gy (average 2183.67Gy).  A range of applicators were used for 
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insertions. Before September 2012, plastic applicators were routinely used while 
after 2012 a titanium applicator set was used. Brachytherapy insertions were 
performed with the following techniques: 95 Tandem and Split Ring, 23 cylinder, 
9 tandem and cylinder, 7 used tandem and ovoids, 2 multiple insertion 
techniques and 36 are undocumented. Patients who are treated with 
brachytherapy also receive external beam radiotherapy. Median EBRT radiation 
dose, dose per fraction and number of fractions were 5000Gy, 200Gy and 25 
fractions respectively. EBRT treatment characteristics are shown in table 3.  
 
A range of side effects were reported in treatment completion summaries written 
by the attending radiation oncologist. Side effects experienced from radiation 
therapy and chemotherapy are documented in table 4. 115 women were 
documented as receiving concurrent cisplatin based chemotherapy, 2 women 
were documented as receiving neoadjuvant chemotherapy, 27 women did not 
receive chemotherapy and there are 107 with unknown chemotherapy status. 
Assessment of the cervical tumor was performed after completion of radiation 
and results collected from treatment completion summaries are seen in table 5. 
114 patients were documented to have had a “complete” tumor response.  
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DISCUSSION 
Cervical cancer is preventable and curable (Maseko et al., 2015).  The incidence 
of cancer diagnoses in developing nations is predicted to reach 70% of all cancer 
diagnoses throughout the world by the year 2030 (Farmer et al., 2010). The 
number of patients who develop cancer and die of the disease is steadily rising 
due to the lack of vaccination and screening programs in the developing world 
(Clinical Radiation Oncology, Gunderson and Tepper). Preventative strategies 
and treatment for cervical cancer are not readily available in developed world, 
and there is also a lack of basic chemotherapy, radiotherapy and surgical 
techniques.  
 
When combined with chemotherapy and external beam radiation therapy, 
brachytherapy can be used to cure locally advanced cervical cancer. As a middle 
income country in Sub-Saharan Africa, Botswana had its population and their life-
expectancy decimated by the AIDS epidemic.  In 2011, the government of 
Botswana recognized the need for in-country brachytherapy, and arranged for a 
public-private partnership (similar to the partnership used to treat patients with 
EBRT). Public oncology patients from Princess Marina Hospital would be treated 
for their cervical cancer with brachytherapy at Gaborone Private Hospital. 
Brachytherapy in Botswana would mean that patients would not have to travel to 
South Africa or Zimbabwe for treatment, which would ideally decrease treatment 
time and allow for patients to have a higher chance of a cure.  Brachytherapy in 
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Botswana also means that the government would not have to pay for 
transportation and housing for patients to receive treatment elsewhere. Ideally, it 
would allow for treatment to be cheaper and more effective.  
 
There were a number of challenges noted with the implementation of 
brachytherapy in other African countries (Einck et al., 2013) that were also 
observed when bringing brachytherapy to Botswana. The radiation source must 
be stored in a secure, shielded environment.  GPH had a brachytherapy bunker 
and installed video cameras near the treatment room ensuring that no one could 
steal the radiation source. There were additional initial problems with equipment 
maintenance. Instrument failures caused treatment delays while waiting for a 
vendor to come in and fix the problem. The 192-Ir source strength is 10 curies 
when it is first delivered, and as it decreases over time it needs to be replaced 
every four months. Currently, logistical and bureaucratic challenges in replacing 
the iridium source every four months contribute to machine downtime and 
occasional delays in treatment. Botswana gained more “electrical independence” 
in 2012, the same year that they started to use brachytherapy. This meant that 
the country experiences occasional power outages, leading to further treatment 
delays. The issues of security, maintenance and power all had to be addressed 
by the government and GPH as they made plans to bring brachytherapy to 
Botswana.  
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Because radiation oncology is a truly multidisciplinary specialty, two other 
challenges in bringing and maintaining brachytherapy in Botswana involved 
building human capital and quality assurance (QA). It is necessary to ensure that 
radiotherapy is delivered in a safe, accurate and effective manner, and for this 
there needs to be an adequate number of trained radiation oncologists, medical 
physicists, dosimetrists, radiation therapists and radiation nurses. Without proper 
staffing and training, there is a risk of misadministering treatment in real-time.  
 
While the team had expertise in treating patients using the LINAC, they did not 
have experience using brachytherapy. Typically, radiation plans are made and 
approved by multiple levels of the oncology team before radiation is administered 
to the patient. These approval processes are still being finalized at GPH to 
ensure that patients receive the correct radiation dose in the correct location.  
The two machines are checked daily and performed by the medical physicist 
before treatment begins.  
 
In the United States, insertion of the applicators occurs while the patient is under 
general anesthesia in the operating room, and patients are subsequently taken to 
get a CT and then to receive brachytherapy. In Botswana, insertion occurs in the 
same room as brachytherapy (not in the operating room) and patients are not 
sedated. Insertion and mobilization of the applicators is painful, and the patient 
must remain still throughout the procedure. This ensures that the applicators are 
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placed in the correct location and allows minimal damage to the surrounding 
tissues. To ensure that the patient does not move while they are moved to get a 
CT, the radiation oncologist packs the area around the applicators to keep them 
stable within the cervix.  
 
The oncology department at GPH was not in possession of an ultrasound at the 
time that the brachytherapy unit was installed. Visualization with ultrasound can 
be helpful during brachytherapy insertions to guide the applicator into place 
within the cervix. In September 2012, during the second visit to Botswana by 
BOTSOGO, the GPH oncology department borrowed a portable ultrasound from 
radiology. While not essential for insertion, ultrasound can help guide the tandem 
in women who have a complex (late stage disease, fibrosed cervix) intra-cervical 
anatomy.   
 
After the Nucletron HDR brachytherapy unit was delivered to GPH, it took almost 
a year to procure the Ir-192 radiation source. This resulted in the buildup of a 
backlog of patients waiting for treatment. Collaboration between BOTSOGO, the 
Botswana-Harvard Partnership, the Botswana Ministry of Health, and the 
oncology community at PMH and GPH allowed for ideal timing of the first trip by 
BOTSOGO to coincide with the arrival of the HDR brachytherapy source. 
Attending radiation oncologists from MGH worked with the attending clinical 
oncologist at GPH on how to successfully perform brachytherapy using a plastic 
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applicator. On a second trip to Botswana in 2012, the BOTSOGO team brought a 
titanium applicator set (donated by Mick Radio-Nuclear Instruments, Inc., Mount 
Vernon, NY, http://micnuclear.com (Bvochara-Nsingo et al., 2014)) to Botswana 
to use at GPH. Since then, insertions have been completed in patients who have 
a more complex intra-cervical anatomy. 46.7% of patients who received radiation 
were documented to have had a fibrosed cervix, which makes insertions more 
challenging. The titanium applicator has been an essential tool in the successful 
implementation of brachytherapy in the country of Botswana.  
 
Even with in-country brachytherapy available, it has been difficult for some 
patients to complete treatment. Oftentimes, women will present with locally 
advanced cervical carcinoma. This makes insertion with plastic or titanium 
applicators difficult, due to fibrosed cervices and delay-induced recurrences 
(Efstathiou et al., 2014). Women may have not completed treatment for a variety 
of reasons, including a range of hematologic and skin toxicities, little or no 
response to treatment, machine downtime and repair, lack of transportation to 
the treatment facility, or loss to follow-up. 15–20% of patients who are referred to 
the oncology department at GPH don’t show up for treatment.  
Transportation is a challenge for many of the patients. The country is 230,000 
square miles (Google, n.d.), and the oncology centers are not geographically 
accessible to most of the country. Patients must travel long distances to receive 
treatment, and many cannot afford it. The Cancer Association of Botswana is 
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always at capacity, as it provides interim housing for cancer patients. Reasons 
for incomplete or delayed treatment are not documented in MOSAIQ or in 
treatment completion summaries and are therefore hard to quantify. Follow-up is 
also a challenge, as many patients complete treatment and they are discharged 
into the public healthcare system There is not a successful follow-up system in 
place for patients in the public sector.  
 
Gaborone Private Hospital and PMH do not have an electronic medical record 
system. Instead, patients have paper charts. In the public sector, patients are 
responsible for bringing their medical records to their appointments. This barrier 
makes research complicated. MOSAIQ is a medical record system that is housed 
at GPH and used in radiation treatment planning. Unfortunately, not all radiation 
treatment is documented accurately and completely in MOSAIQ. Patients who 
were sent to South Africa for brachytherapy (before 2012) have no documented 
brachytherapy in MOSAIQ or in paper records at GPH.  
 
In the United States and other developed countries, the NCCN recommends that 
radiation therapy for cervical cancer, including EBRT and brachytherapy take 8 
weeks. As reported above, the average time from start to finish of radiation 
therapy is 43 days (6.14 weeks). Even though patients did complete treatment 
within the recommended time period, many patients experienced delays in 
receiving radiation. This may be due to inadequate transportation to treatment 
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facilities, machine downtime, national holidays and treatment related toxicity.  
 
Ideally, when countries similar to Botswana develop cancer control plans, they 
will not only improve treatment techniques (such as bringing brachytherapy to the 
country), but they will also begin to use preventative measures, such as 
vaccination and screening. The Botswana-University of Pennsylvania Partnership 
has implemented four mobile-health programs (including the cervical cancer 
screening program) in an attempt to mitigate the cancer burden in Botswana 
(Littman-Quinn et al., 2013). With the implementation of screening programs and 
early cancer detection, but without adequate treatment plans, patients may be 
forced to live and suffer with untreated cancer (Datta et al., 2014). These 
countries must have sufficient treatment resources to handle a large capacity of 
patients with early stage disease. This could eventually affect Botswana, as the 
University of Pennsylvania has developed a successful cervical cancer-screening 
program. As shown in Table 4, the number of cases of cervical cancer treated 
with cervical brachytherapy increases each year. This not only puts strain on the 
limited number of radiation oncologists in the country, but also on the treatment 
machines.  
 
The country of Botswana did not have a radiation therapy unit until the year 
2000. As the countries ARV program became successful, the Ministry of Health 
predicted a rise in cancer diagnosis as HIV patients began to live longer 
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(Livingston, 2012). EBRT can be given with either a Cobalt-60 machine or a 
Linear Accelerator. Currently in Africa, 32% of the EBRT machines are cobalt 
machines, while 68% are Linacs (Page et al., 2014). Many developing nations 
will opt for the Cobalt-60 machine, as it is less expensive to maintain and it is 
simple to use. Linear accelerators are more complex and more expensive to 
maintain on a day-to-day basis, but their use in the developing world is 
increasing due to the fact that they provide superior dosimetry to a Cobalt-60. 
When the HDR brachytherapy unit was obtained in 2001, technical 
considerations needed to be taken into account before it could go into use. The 
iridium source was obtained almost one year after the installation of the machine.  
In the time before the source was installed, a backlog of patients developed and 
had to be eliminated as soon as adequate training was provided. Currently, 
logistical and bureaucratic challenges in replacing the iridium source every four 
months contribute to machine downtime and occasional delays in treatment.  
 
While short-term solutions can be simple to implement, a challenge lies in 
providing longitudinal support to LMICs so that they can provide quality cancer 
care on their own that involves long-term work-force planning (Rosenblatt et al., 
2011). The University of Botswana School of Medicine is in the process of 
educating its first graduating class of Botswana citizens. There are plans to build 
a second radiation bunker in the teaching hospital at the medical school in the 
near future, which will allow many more patients to be treated with radiotherapy. 
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These plans have been underway for a few years, and once the bunker is 
complete and the radiotherapy machines are installed, there will have to be 
adequate staffing and training for the treatment facility. It is important to ensure 
that there are long-term education and training plans with regards to maintaining 
national radiotherapy plans.  
 
Implementation of brachytherapy in Botswana may be able to serve as a model 
to bring brachytherapy in other LMICs. Support from developed institutions 
around the world may prove to be useful in providing higher quality cancer care. 
If each institution “ adopted” a partner institution, they could help to build a 
foundation to provide comprehensive cancer care (Zietman, 2014). The IAEA has 
developed an initiative to help implement radiotherapy around the world, known 
as the “Programme of Action for Cancer Therapy”. Its goals include bringing 
brachytherapy to countries that are currently lacking, through a global public-
private partnership (Rosenblatt et al., 2011).  
 
Study Limitations 
Work is being done in Botswana to complete the data set for the cervical cancer 
patients. Treatment information is not all kept within MOSAIQ, and brachytherapy 
data is kept within the patient’s individual paper charts.  
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While Botswana is a small country in Sub-Saharan Africa, the distance between 
villages and the referral medical centers is large. Often patients will be housed at 
the Cancer Association of Botswana throughout their radiation treatments. After 
treatment, they return home and often do not have routine follow-ups with the 
oncologists in Gaborone. This makes quantifying treatment outcomes difficult, 
and even though we know that brachytherapy is being used to treat cervical 
cancer, cancer-specific survival outcomes and late-toxicities are unknown.  
 
Conclusions 
With an increased effort in cervical cancer screening programs in Botswana, 
cancers may be detected at an earlier stage and therefore have more of a 
chance of a cure. Going forward, information on patients who are being treated 
with cervical brachytherapy can be recorded at time of treatment in an electronic 
database, which will make future research feasible. 
 
Introduction of HDR Brachytherapy to Botswana has led to decreased treatment 
time, reduced complications, increased patient compliance and projected 
improved survival. Implementation of brachytherapy was facilitated by a public-
private partnership and onsite mentorship by expert clinicians. Further research 
is needed to evaluate impact on patient quality of life and survival, and whether 
this experience can be replicated for other tumor sites.  
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• First author poster presentation at ASTRO 2013, Atlanta, 
GA: Addressing the growing cancer burden in the wake 
of the AIDS epidemic in Botswana: A collaborative 
partnership.  
1/10–6/11 Vascular Tissue Biomechanics (VTB) Research 
Assistant—University of Wisconsin, Madison  
• Training and experimentation using an isolated lung 
surgery and setup on rodent model. Performed surgery 
for various trials in the VTB lab and others involved in 
research of pulmonary hypertension.  
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• Isolated lung gender studies performed on mice and 
presented at the National Biomedical Engineering 
Conference, Austin, Texas October 2010, 
Cardiovascular Research Conference and the 
Undergraduate Research Symposium.  
• Research continued at UW-Madison in the VTB lab 
 
Biomedical Engineering Design Projects  
• Automated Uretero-Intestinal Anastamosis with 
Absorbable Staples. Senior design project. Role: Team 
Leader. (Fall 2010–Spring 2012) 
• Prostate Cutting Apparatus: device currently used in UW 
pathology department and to be presented at the United 
States and Canadian Academy of Pathology 2011. 
Role: Team Leader 
• Stereotactic Radiosurgery Head Frame Holder: device 
now used in UW-Madison hospital during stereotactic 
radiosurgery.  Role: Team Leader. Client: Lori Hayes, 
M.S., R.N. (Fall 2009)   
• Tracheotomy Tube Security Device: Role: Team 
communicator (Spring 2009) 
• Blinking Orbital Prosthesis: design of the first blinking 
orbital prosthesis for patients with a complete orbital 
exenteration. Client Greg Gion: Medical Art Prosthetics, 
Madison WI. Role: Team Communicator. (Fall 2008) 
• Water Purification System: Intro to Engineering 160 
Design process; design of a water purification system 
using capacitive deionization and silica nanoparticles to 
deionize and purify water. (Fall 2007) 
 
Volunteer Experience 
MATCH Corps Fellow—MATCH Charter School (August 2011–July 
2012) 
• One year service fellowship providing individualized 
instruction and tutoring for low income, urban high school 
students.  
• Organized logistics for students to participate in college 
trips to New York, Philadelphia, Chicago and Washington 
D.C.  
• Lead a senior AP Calculus seminar to help to reinforce 
complex mathematical concepts.  
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• Americorps program-volunteering in the spring and July 
working in a Boston Public School tutoring students 
 
bWell Center volunteer in the Pediatrics department at Boston 
Medical Center 
Habitat for Humanity Volunteer- Taos, New Mexico (January 2011)  
 
Logistical Director Engineering Expo 2011 – University of Wisconsin, Madison 
